全文获取类型
收费全文 | 445篇 |
免费 | 42篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 7篇 |
基础医学 | 57篇 |
口腔科学 | 8篇 |
临床医学 | 22篇 |
内科学 | 314篇 |
皮肤病学 | 4篇 |
神经病学 | 17篇 |
特种医学 | 1篇 |
外科学 | 22篇 |
综合类 | 6篇 |
预防医学 | 2篇 |
眼科学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 11篇 |
出版年
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 6篇 |
2018年 | 7篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 23篇 |
2011年 | 27篇 |
2010年 | 10篇 |
2009年 | 11篇 |
2008年 | 27篇 |
2007年 | 24篇 |
2006年 | 29篇 |
2005年 | 26篇 |
2004年 | 19篇 |
2003年 | 36篇 |
2002年 | 32篇 |
2001年 | 34篇 |
2000年 | 30篇 |
1999年 | 20篇 |
1998年 | 7篇 |
1997年 | 11篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 24篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 13篇 |
1988年 | 5篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1979年 | 1篇 |
1972年 | 2篇 |
排序方式: 共有488条查询结果,搜索用时 296 毫秒
21.
R A Asherson H M Fei H L Staub M A Khamashta G R Hughes R I Fox 《Annals of the rheumatic diseases》1992,51(4):495-498
Blood samples from 65 patients with primary Sjögren''s syndrome were evaluated for the presence of antiphospholipid antibodies. Increased levels of antiphospholipid antibodies were found in 13 of 65 (20%) of patients. These antiphospholipid antibodies were predominantly of the IgA isotype, in contrast with the IgG isotype antiphospholipid antibodies found in patients with systemic lupus erythematosus (SLE). The presence of IgA antiphospholipid antibodies in the patients with primary Sjögren''s syndrome was not significantly associated with arterial or vascular thrombosis, nor peripheral or central nervous system vasculitis. There was no association with laboratory determined features such as lupus anticoagulant or false positive results of the Venereal Disease Research Laboratory (VDRL) test. Oligonucleotide specific DNA amplification and hybridisation with allele specific probes was used to examine the HLA-D antigens occurring in this group of patients with primary Sjögren''s syndrome. Of 13 patients with antiphospholipid antibodies, seven had the genotype HLA-DR2/DR3. However, compared with the whole group of 65 patients with Sjögren''s syndrome, no increased occurrence of haplotype DR2 or DR3 was noted. These results suggest that gene interaction between DR2 and DR3 may play a part in the production of antiphospholipid antibodies in patients with Sjögren''s syndrome. In contrast with patients with SLE, the IgA antiphospholipid antibodies in patients with Sjögren''s syndrome are not risk factors for thrombosis or vasculitis. The presence of IgA antiphospholipid antibodies in patients with Sjögren''s syndrome probably reflects its production at mucosal sites of inflammation and the absence of vasculopathy may be due to the inability of IgA antibodies to activate complement. 相似文献
22.
Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus 总被引:3,自引:0,他引:3
Karim MY Miranda LC Tench CM Gordon PA D'cruz DP Khamashta MA Hughes GR 《Seminars in arthritis and rheumatism》2002,31(5):289-298
BACKGROUND AND OBJECTIVES: Systemic lupus erythematosus (SLE) may affect all the components of the respiratory system, including upper airways, lung parenchyma, pulmonary vasculature, pleura, and respiratory muscles. The shrinking lung syndrome (SLS) is a rare complication of SLE. This study describes the presenting features, investigation findings, treatment measures, and outcome of 7 patients with SLE and SLS. METHODS: Five patients with SLE/SLE were chosen retrospectively by examination of patient records, and 2 patients were chosen prospectively. All patients attended St. Thomas' Hospital or the Royal London Hospital between 1984 and 2001, with a total population of 2650 patients with SLE. RESULTS: Clinical features included dyspnea and pleuritic chest pain. Chest x-ray films showed small but clear lung fields, or basal atelectasis, with diaphragmatic elevation. No evidence of major parenchymal lung or pleural disease was found on the computerized tomography scan. Lung volumes were reduced on pulmonary function testing (PFT) in a restrictive pattern. Treatment of SLS included theophylline, increase in corticosteroid dosage, and intensification of immunosuppressive medication to include methotrexate or cyclophosphamide. During follow-up, 5 of 7 patients showed objective evidence on PFT of stabilization or improvement. CONCLUSIONS: The long-term prognosis of our SLS patients was reasonable, highlighting the importance of establishing a correct diagnosis and in particular differentiating it from fibrosing lung disease. Immunosuppressive therapy was helpful in stabilizing SLS and improving respiratory symptoms and PFT in some cases. RELEVANCE: SLS represents a rare complication of SLE, and it is important to be aware of its presenting features and prognosis. 相似文献
23.
24.
Manuel Ramos-Casals Candido Diaz-Lagares Maria-Jose Soto-Cardenas Pilar Brito-Zeron María-José Cuadrado Giovanni Sanna Laura Bertolaccini Munther A. Khamashta 《Clinical reviews in allergy & immunology》2011,40(3):159-169
The complexity of the therapeutic approach in lupus nephritis (LN) is increased by the large number of patients who do not
respond to first-line therapies and by relapses after initial clinical remission. The emergence of biological agents has increased
the therapeutic armamentarium available in these complex situations, but their use is limited by the lack of licensing. We
analysed current evidence on the therapeutic use of rituximab in adult LN patients by systematic analysis of seven observational
studies published since 2005 (four in 2009), which included 106 LN patients treated with rituximab. A complete or partial
therapeutic response was achieved in 73 (69%) patients. The response according to the type of LN was stated in 79 cases: 8
(80%) patients with type III LN had a favourable, 26 (67%) of those with type IV, 4 (57%) of those with type V and 18 (78%)
of those with mixed membranous-proliferative LN. The main factors associated with no response were younger age, black race
and lack of CD19+ cell depletion. The lowest rates of complete response were observed in patients with type V LN, especially those with associated
proliferative lesions. Although it is not yet possible to make definite recommendations, the global analysis of these cases
supports the off-label use of rituximab in severe, refractory LN cases. 相似文献
25.
26.
Seronegative antiphospholipid syndrome 总被引:1,自引:0,他引:1
27.
Hughes (antiphospholipid) syndrome (APS) can mimic multiple sclerosis (MS). We analyzed the clinical, laboratory, and imaging findings of MS-like expression in a cohort of patients with APS in an attempt to identify parameters that might differentiate the 2 entities. We studied 27 patients who were referred to our unit with the diagnosis of probable or definite MS made by a neurologist. All patients were referred to our lupus clinic because of symptoms suggesting an underlying connective tissue disease, uncommon findings for MS on magnetic resonance imaging (MRI), atypical evolution of MS, or antiphospholipid antibody (aPL) positivity. aPL, antinuclear antibody (ANA), anti-dsDNA, and anti-extractable nuclear antigen (ENA) antibodies were measured by standard methods. MRI was performed in every patient and compared with MRI of 25 definite MS patients who did not have aPL. An index severity score was calculated based on the size and number of increased signal intensity areas in MRI. In the past medical history, 8 patients with primary APS and 6 with APS secondary to systemic lupus erythematosus (SLE) had had symptoms related to these conditions. Neurologic symptoms and physical examination of the patients were not different from those common in MS patients. Laboratory findings were not a useful tool to distinguish APS from MS. When MRI from APS patients was compared globally with MRI from MS patients, MS patients had significantly increased severity score in white matter (p < 0.001), cerebellum (p = 0.035), pons (p < 0.015), and when all areas were taken together (p < 0.001). Patients with APS had significantly increased scores in the putamen (p < 0.01). No differences were noticed in the degree of atrophy. When taken individually, MRI from APS patients could not be distinguished from MRI from MS patients. Most of the patients with primary APS showed a good response to oral anticoagulant treatment. In patients with secondary APS, the outcome was poorer. Hughes syndrome (APS) and MS can be difficult to distinguish. A careful medical history, a previous history of thrombosis and/or fetal loss, an abnormal localization of the lesions in MRI, and the response to anticoagulant therapy might be helpful in the differential diagnosis. We believe that testing for aPL should become routine in all patients with MS. 相似文献
28.
The aims of this study were to investigate whether anticardiolipin antibodies (aCL) bind to intact (resting or activated) platelets in vitro. Suspensions of resting, activated (with a mixture of thrombin and collagen) and freeze-thawed platelets from healthy subjects were incubated with either affinity-purified aCL or pooled normal human immunoglobulin G (IgG). Platelet-bound IgG was measured by flow cytometric analysis of platelets incubated with a fluorescein-conjugated polyclonal goat anti-human IgG. There was no significant binding of IgG aCL to intact resting or activated platelets, while significant specific binding to freeze-thawed platelets was demonstrated. These results question the theory that aCL bind/activate intact platelets in vivo. 相似文献
29.
30.